Partners Capital Investment Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Partners Capital Investment Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-38,318	Closed	-$610K	–	137
2022 Q4	$610K	Sell	38,318 -3,076	-7%	-$48.1K	0.03%	111
2022 Q3	$677K	Sell	41,394 -103,895	-72%	-$1.68M	0.04%	111
2022 Q2	$2.05M	Hold	145,289	–	–	0.14%	83
2022 Q1	$3.52M	Sell	145,289 -79,541	-35%	-$1.92M	0.17%	79
2021 Q4	$5.25M	Buy	224,830 +17,546	+8%	+$353K	0.24%	77
2021 Q3	$3.44M	Buy	207,284 +85,482	+70%	+$1.65M	0.16%	80
2021 Q2	$2.97M	Buy	121,802 +34,691	+40%	+$783K	0.13%	90
2021 Q1	$2.25M	Buy	87,111 +7,465	+9%	+$329K	0.1%	107
2020 Q4	$4.26M	Buy	+79,646	New	+$3.95M	0.12%	90

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Partners Capital Investment Group's ACAD Position: Q1 2023 in Review

Partners Capital Investment Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 38,318 shares — an estimated $610K sold.

Partners Capital Investment Group first reported a position in ACAD in Q4 2020 and held it in 9 quarters. The position peaked at $5.25M in Q4 2021. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

Partners Capital Investment Group reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Partners Capital Investment Group sold 38,318 Acadia Pharmaceuticals shares in Q1 2023, an estimated $610K.
Partners Capital Investment Group first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Partners Capital Investment Group's Acadia Pharmaceuticals position peaked at $5.25M in Q4 2021.
233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Partners Capital Investment Group's 13F filing for Q1 2023, filed 15 May 2023.